Zoetis moves to acquire the animal genomics unit of Neogen, strengthening its precision animal health capabilities. Zoetis Inc. the world’s leading animal health company, today announced it has entered into…
Roche’s fenebrutinib reaffirms potential as the sole BTK inhibitor for relapsing and primary progressive MS with positive FENhance 1 Phase III results. Roche announced today that the pivotal Phase III…
AbbVie Reports Positive Phase 3 Results for Subcutaneous SKYRIZI® in Crohn’s Disease AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating…
Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening Wisdom Bioscience, a biotechnology company revolutionizing oral cancer diagnostics, has announced the formation of its Scientific Advisory…
Pivotal Study Shows Significant Improvements in Hematocrit Control and Patient Outcomes What does the future hold for patients with polycythemia vera (PV)? Takeda and Protagonist Therapeutics, Inc. have announced a…
Genentech Announces Positive Phase III Results for Fenebrutinib in RMS, Paving the Way for Regulatory Submission Why is the search for effective treatments for multiple sclerosis (MS) more urgent than…
Novocure’s Leadership to Highlight Innovative Cancer Therapy at Prestigious Event Why should healthcare investors and oncology professionals be paying attention to Novocure’s upcoming participation in the Leerink Global Healthcare Conference?…
Cryo-Cell International Sees Revenue Dip and Net Loss in Fiscal 2025 What does a year of financial downturn mean for the world’s first private cord blood bank? Cryo-Cell International, Inc.…
Strategic Equity Incentives to Attract Talent and Drive Innovation Why is attracting and retaining top talent crucial for precision oncology companies? Guardant Health, a leading precision oncology company, is taking…
Prothena’s Strategic Move to Boost Shareholder Confidence and Financial Flexibility Why are biotechnology companies increasingly turning to share repurchase plans to optimize their financial strategies? Prothena Corporation plc, a late-stage…
New Data Supports Next-Phase Development of Targeted Alpha Therapy Why is the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) so challenging? Despite significant advances, the prognosis for men with…
New Data at ASCO GU Highlights Signatera’s Role in Bladder Preservation and Precision Medicine Why are precision medicine tools crucial for improving patient outcomes in genitourinary cancers? Natera, a global…